



(11) **EP 2 616 121 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:

13.05.2020 Bulletin 2020/20

(21) Application number: **11825543.9**

(22) Date of filing: **15.09.2011**

(51) Int Cl.:

A61M 5/142 (2006.01)	A61M 5/168 (2006.01)
A61M 5/14 (2006.01)	A61M 5/172 (2006.01)
G16H 20/17 (2018.01)	A61B 5/00 (2006.01)
A61B 5/021 (2006.01)	A61B 5/024 (2006.01)

(86) International application number:

PCT/SG2011/000314

(87) International publication number:

WO 2012/036636 (22.03.2012 Gazette 2012/12)

(54) **DRUG INFUSION SYSTEM AND METHOD FOR CONTROLLING BLOOD PRESSURE**

MEDIKAMENTENINFUSIONSSYSTEM UND BLUTDRUCKSTEUERUNGSVERFAHREN

SYSTÈME DE PERFUSION DE MÉDICAMENT ET PROCÉDÉ DE SURVEILLANCE DE LA
PRESSION ARTÉRIELLE

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **15.09.2010 US 382945 P**

(43) Date of publication of application:

24.07.2013 Bulletin 2013/30

(73) Proprietor: **Singapore Health Services Pte. Ltd.
Singapore 168753 (SG)**

(72) Inventor: **SIA, Tiong-Heng, Alex
Singapore 168753 (SG)**

(74) Representative: **Talbot-Ponsonby, Daniel
Frederick
Marks & Clerk LLP
Fletcher House
Heatley Road
The Oxford Science Park
Oxford OX4 4GE (GB)**

(56) References cited:

EP-A1- 1 849 412	WO-A2-2006/091650
GB-A- 2 442 875	US-A- 3 923 060
US-A- 4 756 706	US-A- 5 099 852
US-A1- 2004 193 328	US-B1- 7 014 611
US-B1- 7 097 618	

- **DYER R.A. ET AL.: 'Hemodynamic Effects of Ephedrine, Phenylephrine, and the Coadministration of Phenylephrine with Oxytocin during Spinal Anesthesia for Elective Cesarean Delivery' ANESTHESIOLOGY vol. 111, no. 4, October 2009, pages 753 - 765, XP055076282**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 616 121 B1

Description**CROSS-REFERENCE TO RELATED APPLICATION**

5 [0001] This application claims the benefit of priority of US provisional application No. 61/382,945 filed September 15, 2010.

FIELD OF THE INVENTION

10 [0002] Various embodiments relate to a system of controlling the blood pressure of a subject.

BACKGROUND OF THE INVENTION

15 [0003] Perioperative fluctuations of arterial blood pressure (BP) are common and may be associated with adverse outcomes. Despite many years of research, fluctuations in blood pressure (BP), particularly hypotension due to spinal anaesthesia remains a very significant clinical problem for obstetric patients undergoing Caesarean section. This has been reported to be as high as 90% in otherwise healthy women and may be associated with serious morbidity to mother and fetus (Roofthoof & Van 2008, Smiley *et al.* 2006). Maternal arterial hypotension decreases uterine perfusion pressure, leading to intrapartum fetal asphyxia and fetal acidosis (Roberts *et al.* 1995). Severe maternal hypotension also causes
20 maternal cerebral hypoperfusion, resulting in nausea and vomiting. Cases of intractable hypotension and cardiac arrest during spinal anaesthesia for elective caesarean section have been described (Hawthorne & Lyons 1997, Parker *et al.* 1996).

[0004] Various techniques have been used to prevent and manage hypotension. The results from Cochrane database of systematic reviews showed that none of the interventions such as colloids, ephedrine, phenylephrine or lower leg
25 compression, are effective in eliminating this condition (Cyna *et al.* 2006). Vasopressors are drugs commonly used to maintain BP but could lead to significant side effects. One of the difficulties is the large inter-individual variability in the severity of BP changes and their response to treatment. The use of untitrated but necessarily high doses of intravenous vasopressor phenylephrine, in conjunction with intravenous fluids, has been proposed to be nearly obviate the risk of
30 hypotension (Ngan Kee *et al.* 2005) but at the expense of overtreatment (reactive hypertension and compensatory bradycardia). The impact of such an eventuality on the mother and neonate, especially in high risk patients (severe preeclampsia and intra uterine growth retardation) may not be innocuous. Moreover, injudiciously high doses of phenylephrine have been found to compromise uteroplacental circulation (Erkinaro *et al.* 2004) in spite of the Pyrrhic elimination of hypotension.

[0005] Hypotension, for example, blood pressure lower than about 10% of baseline physiologic value of each individual, is a very common side effect in obstetric patients undergoing Caesarean section. This could potentially induce side
35 effects in both mother (nausea, vomiting) and fetus (acidosis) (Ngan Kee *et al.* 2004). However, the current standard technique using the recommended drug called phenylephrine is well known to result in overtreatment of BP, resulting in a significantly higher than normal BP (reactive hypertension, with BP greater than 20% of baseline) in more than 40% of the patients and reactive slowing of maternal heart rate (bradycardia); these may not be innocuous in high risk patients
40 (Ngan Kee *et al.* 2005).

[0006] One of the main causes of overtreatment of BP is the inability to continuously and reliably measure BP non-invasively. In particular, the use of the conventional method of non-invasive BP monitoring (based on the principle of oscillometry) is limited by the time it takes to inflate and subsequently to deflate the cuffs commonly applied to the arm. The lag period and lack of a 'real-time' measurement of BP will lead to failure to refine and react in a timely manner to
45 changes in BP when they occur. In spinal anaesthesia, these changes could be very drastic and sudden - if left untreated could result in negative repercussions to the mother and fetus. The use of an invasive catheter which is inserted into the artery (arterial line) is impractical and not without risk.

[0007] WO 2006/091650 A2 is directed to a system for monitoring physiological parameters and subsequently delivering medication to address each physiological condition.

50 [0008] There remains a need to provide an alternative approach that can prevent or ameliorate the adverse clinical outcomes associated with fluctuations of BP.

SUMMARY OF THE INVENTION

55 [0009] The invention, the scope of which is defined by independent claim 1, provides a system of controlling the blood pressure of a subject. The system comprising a blood pressure data generating unit adapted to generate blood pressure data indicating the blood pressure of the subject; a plurality of pumps, wherein each of the plurality of pumps is adapted to infuse one out of a plurality of different drugs into the subject, each of the plurality of different drugs having a particular

influence on the blood pressure of the subject; a controlling unit adapted to control the plurality of pumps to infuse, in dependence on the blood pressure data, a mix of drugs into the subject which stabilizes the blood pressure of the subject.

BRIEF DESCRIPTION OF THE DRAWINGS

[0010] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings. The methods of figures 1-3 do not constitute embodiments of the invention.

Figure 1 represents a schematic flow diagram 100 illustrating a method of controlling the blood pressure (BP) of a subject.

Figure 2 represents a schematic flow diagram 200 illustrating a method of controlling the blood pressure (BP) of a subject. "HR" represents heart rate of the subject.

Figure 3 represents a schematic flow diagram 300 illustrating a method of controlling the blood pressure (BP) of a subject. Average blood pressure (BP) is arithmetically calculated based on the last three readings of systolic BP at regular time intervals.

Figure 4 represents a system 400 for controlling blood pressure of a subject, according to various embodiments.

Figure 5 shows an image displaying the components of a closed-loop' dual-pump automated system (CLDPAS) for controlling the blood pressure of a subject, according to various embodiments. "CNAP" stands for Continuous Noninvasive Arterial Pressure.

Figure 6 represents a schematic diagram 500 of a closed-loop controller for infusion of phenylephrine or ephedrine drugs during caesarean section under spinal anaesthesia, according to various embodiments. "CNAP_Sys" represents CNAP Systolic BP (finger); Baseline NBP represents Noninvasive BP (cuff); Baseline HR represents HR before start; Mean CNAP_Sys10s represents Mean CNAP from 1s to 10s; Mean CNAP_Sys15s represents Mean CNAP from 10s to 15s.

DETAILED DESCRIPTION OF THE INVENTION

[0011] The following detailed description refers to accompanying drawings that show, by way of illustration, specific details and embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention. Other embodiments may be utilized and structural, logical changes may be made without departing from the scope of the invention. The various embodiments are not necessarily mutually exclusive, as some embodiments can be combined with one or more other embodiments to form new embodiments.

[0012] In the context of various embodiments, the term "about" or "approximately" as applied to a value may encompass the exact value and a variance of $\pm 5\%$ of the value.

[0013] An alternative and individualized approach to maintain hemodynamic stability has been found which can prevent or ameliorate the adverse clinical outcomes associated with fluctuations of blood pressure. Without wishing to be bound by theory, the systolic blood pressure can be maintained within about 10% of the baseline value. Therefore, the neonatal outcomes (APGAR scores, umbilical cord pH) and the profile of maternal side effects (hypotension, hypertension, nausea, vomiting, bradycardia and maternal satisfaction) will favour patients utilizing the methods and systems of the invention compared to those who receive the standard techniques in the art.

[0014] The method of controlling the blood pressure of a subject, which does not constitute an embodiment of the invention, is based on the independent control of a plurality of pumps supplying drugs into subject, in dependence on the blood pressure data of the subject.

[0015] The method includes generating blood pressure data indicating the blood pressure of the subject; controlling a plurality of pumps to infuse, in dependence on the blood pressure data, drugs into the subject, wherein each of the plurality of pumps is adapted to infuse one out of a plurality of different drugs into the subject, and wherein each of the plurality of different drugs has a particular influence on the blood pressure of the subject; wherein the plurality of pumps is controlled such that, in dependence on the blood pressure data, a mix of drugs is infused into the subject which stabilizes the blood pressure of the subject.

[0016] The plurality of pumps is controlled to infuse drugs into the subject if the blood pressure falls below a predetermined blood pressure threshold value. The blood pressure of the subject can be determined arithmetically so long as the value is in relation to an average blood pressure value or range. An average blood pressure value can, for example, be calculated from a summation of at least two blood pressure values determined at regular time intervals of about 10, about 15 or about 20 seconds. The blood pressure threshold value of the subject can refer to a baseline blood pressure that is calibrated according to the methods described herein. In various embodiments, the predetermined blood pressure threshold value is below about 90%, for example, about 89%, about 88%, about 87%, about 86%, about 85%, about

84%, about 83%, about 82%, about 81%, or about 80% of the normal blood pressure, to mention only a few. Blood pressure is typically represented as systolic pressure over diastolic pressure. The systolic pressure refers to the pressure in the arterial system at its highest, and diastolic pressure refers to the lowest pressure. It is usually measured in mm Hg. Normal pressure is 120/70 on average, but normal for an individual can vary with the height, weight, fitness level, health, emotional state, age, etc., of a person. Although there is no clear dividing line between normal and high blood pressure, "hypotension" can include absolute hypotension as may be defined medically (such as systolic blood pressure below 90 mm Hg). Within the context of various embodiments, the method can comprise treating or preventing hypotension of a subject.

[0017] The method comprises generating heart rate data reflecting a heart rate of the subject, wherein the plurality of pumps is controlled in dependence on the heart rate. The heart rate of the subject can be determined arithmetically so long as the value is in relation to an average heart rate value or range. An average heart rate value can, for example, be calculated from a summation of at least two heart rate values determined at regular time intervals of about 10, about 15 or about 20 seconds.

[0018] A first pump of the plurality of pumps is controlled to infuse a first drug into the subject if the heart rate of the subject exceeds a predetermined heart rate threshold value. The predetermined heart rate threshold value may refer to the heart rate of the subject that is determined before the method of the invention is carried out. The predetermined heart rate threshold value can for example refer to the resting heart rate of a healthy subject. Typically, a normal heart rate in adults is in the range of about 60 to about 80 beats per minute (bpm). Rates below about 60 bpm can be referred to as bradycardia, and rates above 60 bpm can be referred to as tachycardia. In various embodiments, the predetermined heart rate threshold value is below about 60 bpm, for example, about 59 bpm, about 58 bpm, about 57 bpm, about 56 bpm, about 55 bpm, about 54 bpm, about 53 bpm, about 52 bpm, about 51 bpm, about 50 bpm, about 48 bpm, about 45 bpm, about 40 bpm, to mention only a few.

[0019] A second pump of the plurality of pumps is controlled to infuse a second drug into the subject if the heart rate of the subject falls below the predetermined heart rate threshold value.

[0020] A plurality of pumps may for example be two, three, four, five six or any higher number of pumps. The pump can refer to any device capable of delivering at least one drug, in particularly a pump that can provide or infuse drug from a syringe for example, in a controlled manner. Each of the plurality of pumps is adapted to infuse at least one out of a plurality of different drugs, that is for example, a first pump of the plurality of pumps is adapted to infuse a first drug; a second pump of the plurality of pumps is adapted to infuse a second drug; a third pump of the plurality of pumps is adapted to infuse a third drug; a fourth pump of the plurality of pumps is adapted to infuse a fourth drug, and so on. The at least one drug to be infused to the subject has a particular influence on the blood pressure of the subject, so long as the blood pressure of the subject is stabilized. The drug can, for example, be any drug that treats or prevents hypotension, any vasopressor drugs including but not limited to phenylephrine, ephedrine and their derivatives thereof.

[0021] The drugs can be injected into the subject continuously in regular time intervals until the blood pressure exceeds the blood pressure threshold value. The regular time intervals can be in the range of between about 10 to 40 seconds, between about 10 to 30 seconds, between about 10 to 20 seconds, between about 15 to 30 seconds, between about 15 to 20 seconds, about 25 seconds, about 20 seconds, about 15 seconds, or about 10 seconds.

[0022] Phenylephrine can be injected with a dose of between about 0.01 mg to 0.2 mg; about 0.01 mg to 0.1 mg; about 0.01 mg to 0.05 mg; about 0.025 mg to 0.2 mg; about 0.05 mg to 0.2 mg; about 0.01 mg to 0.2 mg; about 0.1 mg to 0.2 mg; 0.05 mg or 0.025 mg at regular time intervals. In various embodiments, ephedrine can be injected with a dose of between about 0.5 mg to 4 mg; about 0.5 mg to 3.5 mg; about 0.5 mg to 3 mg; about 0.5 mg to 2.5 mg; about 0.5 mg to 2 mg; about 0.5 mg to 1.5 mg; about 0.5 mg to 1 mg; 4 mg, 2 mg or 1 mg at regular time intervals.

[0023] The blood pressure data and the heart rate data are collected in real time. In various embodiments, the blood pressure data is collected using optical sensors. The optical sensors can be integrated into a cuff which is adapted to apply mechanical pressure on the subject.

[0024] Various embodiments of the invention provide a system of controlling the blood pressure of a subject. The system includes a blood pressure data generating unit adapted to generate blood pressure data indicating the blood pressure of the subject, a plurality of pumps, wherein each of the plurality of pumps is adapted to infuse one out of a plurality of different drugs into the subject, each of the plurality of different drugs having a particular influence on the blood pressure of the subject, a controlling unit adapted to control the plurality of pumps to infuse, in dependence on the blood pressure data, a mix of drugs into the subject which stabilizes the blood pressure of the subject.

[0025] In various embodiments, the blood pressure data generating unit is adapted to generate the blood pressure data in real time. The blood pressure data generating unit can in some embodiments be a non-invasive blood pressure data generating unit, and can for example be a hemodynamic monitoring device. In some embodiments, the blood pressure data generating unit can include optical sensors. The optical sensor can, in some embodiments, be integrated in a cuff wherein the cuff is adapted to apply mechanical pressure onto the subject. Blood pressure can thus be measured by way of an infrared light optical sensor measuring pulse pressure in the subject's fingertip for example. The blood pressure data generating unit can also include a display unit adapted to display the blood pressure data.

[0026] In various embodiments, the controlling unit may comprise means for receiving information from the blood pressure data generating unit, and means for sending information to the plurality of pumps. The process and related means may be implemented using hardware, software or a combination thereof and may be implemented, for example, in one or more computer systems or other processing systems.

[0027] In various embodiments, the system further includes a heart rate data generating unit adapted to generate heart rate data reflecting heart rate of the subject. The heart rate data generating unit can include any heart rate measuring device for example, heart rate monitor, or pulse oximeter, so long as the heart rate of the subject can be determined.

[0028] The controlling unit controls the plurality of pumps in dependence on the heart rate data. In various embodiments, the controlling unit is adapted to control a first pump of the plurality of pumps to infuse a first drug into the subject if the heart rate of the subject exceeds a predetermined heart rate threshold value. In other embodiments, the controlling unit is adapted to control a second pump of the plurality of pumps to infuse a second drug into the subject if the heart rate of the subject falls below the predetermined heart rate threshold value.

[0029] In order that the invention may readily understood and put into practical effect, particular embodiments will now be described with reference to the figures. It should also be appreciated that any of the components or sub-components discussed herein with regards to various embodiments of the present invention may be communicated with one another with data or signal transfer via a variety of communication interfaces. For example, in the form of signals or data may be electronic, electromagnetic, optical or other signals capable of being received by communications interface and components and subcomponents of the present invention. The communication may, for example be implemented using serial ports, wire or cable, fiber optics, a phone line, a cellular phone link, or other communication channels (hard wire or wireless included). Similarly, any material, fluid or medium transported between components or subcomponents described herein with regard to the various embodiments of the invention may include a variety of types, such as, but not limited to conduits, tubes, lumen, channels, needles, catheters or the like.

[0030] Figure 1 represents a schematic flow diagram **100** illustrating a method of controlling the blood pressure (BP) of a subject. The BP reading of a subject can be taken by a blood pressure data generating unit **120** according to various embodiments of the invention. This subject may for example be a human subject. The subject may for example be a patient undergoing a perioperative procedure. The subject can be an obstetric patient. The BP of the subject is monitored at step **140** and an average BP can be arithmetically calculated based on final three readings of the systolic blood pressure of the subject. When criterion **160** is met, in which the BP falls below a predetermined BP threshold value, the plurality of pumps **180** is controlled to infuse drugs into the subject. When criterion **150** is met, in which BP exceeds the predetermined BP threshold value, the plurality of pumps **170** will be deactivated and no infusion of drugs occur.

[0031] Figure 2 represents a schematic flow diagram **200** illustrating a method of controlling the blood pressure (BP) of a subject. The BP reading of a subject is taken by a blood pressure data generating unit **120** according to various embodiments of the invention, the BP is monitored and an average BP is determined at step **140**. When both criteria **160** and **210** are met in which BP of the subject falls below a predetermined BP threshold value and heart rate (HR) exceeds a predetermined HR threshold value, a first pump **220** of a plurality of pumps is controlled to infuse a first drug. When both criteria **160** and **230** are met in which BP of the subject falls below a predetermined BP threshold value and HR falls below a predetermined HR threshold value, a second pump **240** of a plurality of pumps is controlled to infuse a second drug. When criterion **150** is met, in which BP exceeds the predetermined BP threshold value, the plurality of pumps **170** will be deactivated and no infusion of drugs occur.

[0032] Figure 3 represents a schematic flow diagram **300** illustrating a method of controlling the blood pressure of a subject. Such a method according to various embodiments is carried out with the purpose to maintain the systolic blood pressure (SBP) at 90% of baseline blood pressure. The subject undergoes regional anesthesia **310** and BP is taken and monitored **320**. When the SBP of the subject is below 90% of baseline blood pressure **330** and heart rate is below 60 beats per minute **360**, both infusion pumps **350** and **370** for phenylephrine 25mcg and ephedrine 2mg will be activated. If the heart rate is above or equal to 60 beats per minute **340**, only infusion pump **350** for phenylephrine 25mcg will be activated. On the other hand, if the systolic blood pressure is above 90% of baseline blood pressure **380**, neither of the pumps will be activated **390**. Without wishing to be bound by theory, the method and system according to the invention provide not only continuous measurements of blood pressure and heart rate without invasive blood pressure monitoring, it also provide instantaneous administration of vasopressors to restore hemodynamic stability.

[0033] Figure 4 illustrates a system **400** for controlling blood pressure of a subject, according to various embodiments. The system can be a closed-loop' dual-pump automated system (CLDPAS) integrated by a method according to various embodiments, to regulate patients' hemodynamic status during anaesthesia. The system can also be operated under a fixed rate mode. The blood pressure of a subject **410** is measured by a sensor **420**. The sensor can be integrated into a finger cuff which is adapted to apply mechanical pressure on the subject. Finger cuff from Infinity® CNAP™ SmartPod can be used. The blood pressure data can be displayed by the blood pressure data generating unit **430**, and exported continuously to controlling unit **440**. The controlling unit **440** may be a computer programmed to implement the methods according to the present invention, provide a user interface and to control communication through serial ports (RS 232) with the blood pressure data generating unit **430** such as the Infinity® CNAP™ hemodynamic Monitor (Draeger Medical,

Lübeck, Germany) and the plurality of pumps **450** for example the infusion system (B. Braun, Melsungen AG, Germany). Information will be sent to activate either one of the plurality of pumps **450** or neither based on the methods of the invention. As an illustrative example, the drugs phenylephrine and ephedrine were prepared at a concentration of 100 microgram /ml and 8mg /ml, respectively, in two 50-ml syringe that was connected via fine-bore extension tubing to the patient's intravenous cannula by a three-way stopcock without using a oneway valve.

[0034] Figure 5 shows an image displaying the components of a closed-loop' dual-pump automated system (CLDPAS) for controlling the blood pressure of a subject, according to various embodiments. "CNAP" stands for Continuous Non-invasive Arterial Pressure.

[0035] Figure 6 represents a schematic diagram **500** showing the basic operation of a closed-loop controller for infusion of phenylephrine or ephedrine drugs during caesarean section under spinal anaesthesia, according to various embodiments. The closed-loop' dual-pump automated system (CLDPAS) system utilizes the Infinity® CNAP™ (Continuous Noninvasive Arterial Pressure) SmartPod and the data generated will be fed-back to a microprocessor to tightly regulate the functions of two infusion pumps for drugs to regulate blood pressure, i.e. vasopressors, namely phenylephrine and ephedrine. Infinity® CNAP™ gives an instantaneous, continuous measure for arterial BP. The photoplethysmograph sensors use an infrared light source and a light detector measure the blood volume in the finger arteries and a direct measure of arterial real-time BP is derived from the sensor cuff pressure. This enables BP calculated by beat-to-beat and a high resolution arterial pressure waveform can be obtained to allow a comprehensive view of the patient's status. The maternal systolic BP will be continuously fed back to the computer integrated infusion pumps and in response, a preset volume of vasopressors will be infused. The computer-controlled infusion program used was developed using Microsoft .Net 3.5 under the Windows XP operating system. By user selection, the program can be switched between fixed rate mode and closed-loop feedback mode.

[0036] Referring to the schematic diagram of Figure 6, the basic operation of the system running under closed-loop feedback mode is shown. At step **S520**, the baseline heart rate ("Baseline HR") and baseline blood pressure ("Baseline NBP") are calibrated. The blood pressure **S530** ("Final Mean CNAP_Sys") of a subject is calculated by averaging the total of mean blood pressure value from 1s to 10s at step **S540** ("Mean CNAP_Sys10s") and mean blood pressure value from 10s to 15s at step **S550**. The heart rate **S560** ("Final Mean HR") of the subject is calculated by averaging the total of mean heart rate value from 1s to 10s ("Mean HR at 10s") at step **S570** and mean heart rate value from 10s to 15s at step **S580** ("Mean HR at 15s"). If criterion 1 is fulfilled at step **S590** in which the blood pressure ("Final Mean CNAP_Sys") of the subject falls below the baseline blood pressure ("Baseline NBP"), and criterion 1.1 is fulfilled at step **S600** in which the heart rate (HR) of the subject exceeds or is equal to the baseline heart rate, pump 1 **S610** will be activated to infuse phenylephrine for 20s at 200ml/hr. When criteria 1 is fulfilled at step **S590** in which the blood pressure ("Final Mean CNAP_Sys") of the subject falls below the baseline blood pressure ("Baseline NBP") and criteria 1.1 is not fulfilled at step **S600** in which the heart rate (HR) of the subject falls below the baseline heart rate, both pump 1 **S610** and pump 2 **S620** will be activated to infuse phenylephrine and ephedrine respectively for 20s at 200ml/hr. If criterion 2 is fulfilled at step **S630** in which the blood pressure ("Final Mean CNAP_Sys") of the subject exceeds or is equal to the baseline blood pressure ("Baseline NBP"), the pumps will be deactivated and infusion will stop **S640**. The maternal systolic BP will be monitored **S650** and continuously fed back to the computer integrated infusion pumps and in response, a preset volume of vasopressors will be infused.

[0037] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the scope of the independent claim also form part of the invention.

[0038] Other embodiments are within the following claims as follows. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

EXAMPLES

[0039] A Closed Loop Dual Pump Automated System (CLDPAS) arterial pressure control system integrated by a unique clinical algorithm to allow a greater control patients' hemodynamic status during anaesthesia is developed. This system utilizes the Infinity® CNAP™ (Continuous Noninvasive Arterial Pressure) SmartPod whereby the data generated will be fed-back to a microprocessor to tightly regulate the functions of two infusion pumps for drugs to regulate blood pressure, i.e. vasopressors, namely, phenylephrine and ephedrine, via a custom-made USB connection.

[0040] CLDPAS is able to continuously and accurately measure beat-to-beat arterial BP via a non-invasive monitor plus automate and refine the infusion of vasopressors through computer integrated infusion pumps.

[0041] The preliminary prospective cohort study was conducted to assess the efficacy of the CLDPAS arterial pressure control system to treat hypotension during a standardised spinal anaesthetic for Caesarean delivery.

Methods

[0042] Institutional approval was obtained from Singapore Health Services Centralised Institutional Review Board. The CLDPAS arterial pressure system was developed by Professor Alex Sia.

[0043] 41 women were recruited in this preliminary study. The inclusion criteria included ASA 1 and 2 women and term singleton pregnancies scheduled for an elective caesarean section under spinal anaesthesia. Women with pre-existing or pregnancy-induced hypertension, cardiovascular or cerebrovascular diseases, known foetal abnormality or any signs of onset of labour were not included. Oral premedication with sodium citrate 0.3M was given prior to arrival at the operating theatre. A baseline systolic blood pressure was calculated as the mean of three recordings and this value was used as the target systolic blood pressure in the CLDPAS arterial pressure system. An 18G cannula was inserted into a forearm vein under local anaesthesia and connected this to a 500ml Hartmann's solution bag suspended about 1.5m above the operating table. Blood (3mls) was withdrawn and collected in the EDTA tube for the genetic arm of the study (genotyping for adrenoceptor genetic polymorphism).

[0044] All subjects were monitored by electrocardiography, pulse oximetry and blood pressure assessment with the Infinity CNAP system. No intravenous prehydration was given. The woman would be placed in the sitting position for induction of spinal anaesthesia. After skin infiltration with lignocaine, a 27G pencilpoint needle was inserted at the L3-L4 interspace and 2.2ml 0.5% hyperbaric bupivacaine with 15mcg fentanyl and 100mcg morphine was administered intrathecally. The patient was immediately returned to the tilted supine position. Directly after the intrathecal injection, the CLPAS arterial pressure system and rapid intravenous fluid infusion (coload) was initiated.

[0045] The system integrates a unique clinical algorithm using the Infinity CNAP to a microprocessor to regulate blood pressure by treating hypotension by activating vasopressor infusion pumps. Phenylephrine bolus of 50mcg will be activated when the systolic blood pressure is reduced by more than 10% of the baseline systolic blood pressure without bradycardia i.e heart rate less than 60 beats per minute. Ephedrine bolus of 4mg will be activated when the systolic blood pressure is reduced by more than 10% of the baseline blood pressure associated with bradycardia. The attending anaesthetist was allowed to give additional boluses of phenylephrine, ephedrine or atropine if there was severe hypotension (systolic blood pressure less than 65mmHg) or severe bradycardia (heart rate less than 45 bpm).

[0046] The dermatomal level of loss of cold sensation is taken at 5 minutes after intrathecal injection. Adverse effects such as nausea and vomiting would also be reported. Demographic data such as age, weight, height, baseline systolic blood pressure and baseline heart rate were recorded. Clinical outcomes including time of intrathecal injection, time of lying in supine position, time of skin incision, time of delivery, time of end of surgery, dose of phenylephrine and ephedrine before delivery, total dose of phenylephrine and ephedrine, total volume of intravenous fluid, maximum and minimum systolic blood pressure, maximum and minimum heart rate, APGAR score at 1 and 5 minutes and birthweight were also recorded.

[0047] Statistical analyses in this study were performed using SPSS 16.0. The demographic data and characteristics of the patients were analysed using median [range] [interquartile range] and mean (standard deviation). The clinical outcomes of the patients were analysed using median [range][interquartile range]. The incidence of phenylephrine and ephedrine requirement and side effects (nausea, vomiting) were reported as number (percentage).

Results

[0048] Forty one patients completed the preliminary study with no drop-outs. There were no failures from the spinal anaesthesia requiring conversion to general anaesthesia. The characteristics of the patients were summarized in Table 1.

[0049] Thirty eight patients (92.6%) required phenylephrine throughout the caesarean delivery. Thirty seven (90.2%) required phenylephrine before the fetus delivery. Ten patients (24.4%) required ephedrine during the Caesarean delivery. Eight patients required ephedrine before delivery. Two patients experienced nausea during the Caesarean section, but no patients had any episode of vomiting. The attending anaesthetist did not need to administer additional phenylephrine, ephedrine or atropine.

[0050] The clinical outcomes of the patients are summarized in Table 2.

[0051] All 41 patients agreed for the genetic screening for adrenoceptor genetic polymorphism. The blood samples were collected during intravenous cannulation using EDTA tubes.

Discussion

[0052] A Closed Loop Dual Pump Automated System (CLDPAS) arterial pressure control system for maintaining maternal blood pressure during spinal anaesthesia for caesarean section according to various embodiments of the invention is described herein. The present system did not require any additional intervention from the anesthetist and resulted in good clinical outcomes for the women and baby. A minority of women (4.9%) experienced nausea during the caesarean section. There was no occurrence of vomiting and all babies had APGAR 9 at 5 minutes.

[0053] Most patients required the phenylephrine automated boluses from the CLDPAS arterial pressure system during the Caesarean section. The CLDPAS arterial pressure system has the unique ability to infuse automated ephedrine boluses. Eight out of 41 patients (19.5%) had bradycardia associated with hypotension that required ephedrine boluses. Without wishing to be bound by theory, this finding suggests that the dual pump setup according to various embodiments of the invention is useful to counteract the effects of hypotension and bradycardia that may coexist under these circumstances. The ability of CLDPAS to rapidly and effectively respond to hemodynamic changes is facilitated by the Infinity CNAP system that enables a near continuous non-invasive monitoring of systolic blood pressure when compared to the currently available systems that provide only intermittent blood pressure readings. As a corollary, the concept CLDPAS would also be applicable to any system that enables either invasive (achieved by transduction via an intraarterial catheter) or non-invasive continuous blood pressure monitoring devices. On the other hand, the often used intermittent non-invasive blood pressure monitoring (typically undertaken by using a repeatedly inflating a cuff on the arm and commonly based on the principle of oscillometry) is unable to perform reliably if the frequency between two measurements is shorter than 1-minute, even if the process can fully automated. It is also more prone to artefacts such as shivering. The CLDPAS arterial pressure system would average the systolic blood pressure readings over each 15 second epochs to allow an almost 'real time' response to changes of blood pressure below the 10% of the baseline value.

[0054] As the reference of the Infinity CNAP was based on the conventional non-invasive blood pressure monitoring, the Infinity CNAP was recalibrated every 10-15 minutes. Therefore the CLDPAS according to the invention is found as a reliable arterial pressure control system during spinal anaesthesia for caesarean section.

Table 1

Characteristics of patients undergoing Caesarean section with CLDPAS arterial pressure system. Values are median [range] or mean (SD).	
Age; years	32.9 (5.0)
Weight; kg	68.1 (10.4)
Height; cm	159.0 (5.4)
Baseline systolic blood pressure; mmHg	123 [104-140][116-131]
Baseline heart rate; bpm	78 [65-97][70-85]

Table 2

Clinical outcomes of patients undergoing Caesarean section with CLDPAS arterial pressure system. Values are median [range] [IQR].	
Block height at 5 minute; dermatome	T3 [T1-T6]
Spinal to supine position time; min	2 [1-6]
Spinal to delivery time; min	17 [9-46]
Spinal to end of surgery time; min	43 [28-107]
Dose of phenylephrine before delivery; mcg	250 [0-1200]
Dose of ephedrine before delivery; mg	0 [0-24]
Total dose of phenylephrine; mcg	800 [0-2150]
Total dose of ephedrine; mg	0 [0-28]
Total fluids; mls	1500 [1000-2500]
Maximum systolic blood pressure; mmHg	130 [109-157]
Maximum heart rate; bpm	108 [82-153]
Minimum systolic blood pressure; mmHg	84 [69-125]
Minimum heart rate; bpm	59 [47-85]
APGAR score at 1 min	9 [6-9]
APGAR score at 5 min	9 [9-9]

(continued)

Clinical outcomes of patients undergoing Caesarean section with CLDPAS arterial pressure system. Values are median [range] [IQR].	
---	--

Birthweight; gm	3145 [2426-4642]
-----------------	------------------

REFERENCES

[0055]

Cyna AM, Andrew M, Emmett RS, Middleton P, Simmons SW. Techniques for preventing hypotension during spinal anaesthesia for caesarean section. Cochrane Database Syst Rev, 2006(4):CD002251.

Erkinaro T, Mäkilä K, Kavasmaa T, Alahuhta S, Räsänen J. Effects of ephedrine and phenylephrine on uterine and placental circulations and fetal outcome following fetal hypoxaemia and epidural-induced hypotension in a sheep model. Br J Anaesth. 2004. 93(6):825-32.

Hawthorne, L. and Lyons G. Cardiac arrest complicating spinal anaesthesia for caesarean section. Int J Obstet Anesth, 1997. 6(2):126-9.

Ngan Kee WD, Khaw KS, Ng FF. Comparison of phenylephrine infusion regimens for maintaining maternal blood pressure during spinal anaesthesia for Caesarean section. Br J Anaesth. 2004. 92(4):469-74.

Ngan Kee WD, Khaw KS, Ng FF. Prevention of hypotension during spinal anaesthesia for cesarean delivery: an effective technique using combination phenylephrine infusion and crystalloid cohydration. Anesthesiology. 2005. 103(4):744-50.

Parker J, Balis N, Chester S, Adey D. Cardiopulmonary arrest in pregnancy: successful resuscitation of mother and infant following immediate caesarean section in labour ward. Aust N Z J Obstet Gynaecol, 1996. 36(2):207-10.

Roberts SW, Leveno KJ, Sidawi JE, Lucas MJ, Kelly MA. Fetal acidemia associated with regional anesthesia for elective cesarean delivery. Obstet Gynecol, 1995. 85(1):79-83.

Roofthoof, E. and M. Van de Velde, Low-dose spinal anaesthesia for Caesarean section to prevent spinal-induced hypotension. Curr Opin Anaesthesiol, 2008. 21(3):259-62.

Smiley RM BJ, Negron M, Landau R. beta2-adrenoceptor genotype affects vasopressor requirements during spinal anaesthesia for cesarean delivery. Anesthesiology, 2006. 104(4):644-50.

Claims

1. A system of controlling a blood pressure of a subject, comprising:

a blood pressure data generating unit (430) adapted to generate blood pressure data indicating the blood pressure of the subject, and further adapted to calibrate a blood pressure baseline for the subject and select a blood pressure threshold corresponding to said blood pressure baseline;

said blood pressure data generating unit adapted to calculate a mean final blood pressure indicating the blood pressure of the subject during a pre-determined period, such that, the final mean blood pressure includes a greater weight to blood pressure measured in a later part of the pre-determined period than during an earlier part; wherein the blood pressure is generated by a non-invasive blood pressure data generating unit, the blood pressure data generating unit being non-invasive;

a heart rate data generating unit adapted to generate heart rate data indicating a heart rate of the subject, and further adapted to calibrate a heart rate baseline for the subject and select a heart rate threshold corresponding to said heart rate baseline;

a plurality of pumps (450), wherein each of the plurality of pumps is adapted to infuse one out of a plurality of different drugs into the subject, each of the plurality of different drugs having a particular influence on the blood

pressure of the subject;

a controlling unit (440) adapted to control the plurality of pumps to infuse, in dependence on the final mean blood pressure relative to the blood pressure threshold and the heart rate data relative to the heart rate threshold, a mix of drugs into the subject which stabilizes the blood pressure of the subject,

characterised in that

the plurality of pumps are controlled such that, if the final mean blood pressure of the subject falls below the blood pressure threshold and heart rate exceeds the heart rate threshold, a first pump (220) of the plurality of pumps is controlled to infuse a first drug;

if the final mean blood pressure of the subject falls below the blood pressure threshold and heart rate falls below the heart rate threshold, a second pump (240) of the plurality of pumps is controlled to infuse a second drug; if blood pressure exceeds the blood pressure threshold, the plurality of pumps (170) is deactivated and no infusion of drugs occur;

wherein the controlling unit is adapted to cause the injection of drugs into the subject in regular time intervals ranging between 15 and 30 seconds until the blood pressure exceeds the blood pressure threshold.

2. The system according to claim 1, wherein the blood pressure threshold falls below 90% of a baseline blood pressure.

3. The system according to claim 1 or 2, wherein the heart rate threshold falls below 60 beats per minute.

4. The system according to any preceding claim, wherein the first drug is Phenylephrine.

5. The system according to any preceding claim, wherein the second drug is Ephedrine.

6. The system according to claim 4 or 5, wherein the controlling unit is adapted to cause injection of Phenylephrine with a dose of between about 0.01 mg to 0.2 mg or 0.025 mg at regular time intervals.

7. The system according to claim 5 or 6, wherein the controlling unit is adapted to cause injection of Ephedrine with a dose of between about 0.5 mg to 4 mg or 2 mg at regular time intervals.

8. The system according to any preceding claim, wherein the blood pressure data generating unit is adapted to generate the blood pressure data in real time.

9. The system according to any preceding claim, wherein the blood pressure data generating unit comprises optical sensors.

10. The system according claim 9, wherein the blood pressure data generating unit is a cuff into which the optical sensors are integrated, wherein the cuff is adapted to apply mechanical pressure onto the subject.

Patentansprüche

1. System zur Steuerung eines Blutdrucks eines Subjekts, Folgendes beinhaltend:

eine Blutdruckdatenerzeugungseinheit (430), welche geeignet ist, Blutdruckdaten zu erzeugen, welche den Blutdruck eines Subjekts angeben, und zudem geeignet ist, eine Blutdruck-Baseline für das Subjekt zu kalibrieren und einen dieser Blutdruck-Baseline entsprechenden Blutdruckschwellenwert für das Subjekt auszuwählen;

wobei die Blutdruckdatenerzeugungseinheit geeignet ist, einen mittleren Endblutdruck zu berechnen, welcher den Blutdruck des Subjekts über einen vorbestimmten Zeitraum angibt, in einer Weise, dass der mittlere Endblutdruck eine größere Gewichtung des in einem späteren Teil des vorbestimmten Zeitraums als in einem früheren Teil gemessenen Blutdrucks enthält;

wobei der Blutdruck durch eine nicht invasive Blutdruckdatenerzeugungseinheit erzeugt wird, wobei die Blutdruckdatenerzeugungseinheit nicht invasiv ist;

eine Herzfrequenzdatenerzeugungseinheit, welche geeignet ist, Herzfrequenzdaten zu erzeugen, welche die Herzfrequenz eines Subjekts angeben, und zudem geeignet ist, eine Herzfrequenz-Baseline für das Subjekt zu kalibrieren und einen dieser Herzfrequenz-Baseline entsprechenden Herzfrequenzschwellenwert für das Subjekt auszuwählen;

eine Vielzahl von Pumpen (450), wobei jede der Vielzahl von Pumpen geeignet ist, eines einer Vielzahl unter-

schiedlicher Medikamente in das Subjekt zu infundieren, wobei jedes der Vielzahl von unterschiedlichen Medikamenten einen besonderen Einfluss auf den Blutdruck des Subjekts besitzt;
 eine Steuereinheit (440), welche geeignet ist, die Vielzahl von Pumpen zu steuern, um in Abhängigkeit vom mittleren Endblutdruck in Bezug auf den Blutdruckschwellenwert und von den Herzfrequenzdaten in Bezug auf den Herzfrequenzschwellenwert eine Mischung von Medikamenten in das Subjekt zu infundieren, welche den Blutdruck des Subjekts stabilisiert, **dadurch gekennzeichnet, dass**
 die Vielzahl von Pumpen in einer Weise gesteuert wird, dass,
 wenn der mittlere Endblutdruck des Subjekts unter den Blutdruckschwellenwert fällt und die Herzfrequenz den Herzfrequenzschwellenwert überschreitet, eine erste Pumpe (220) der Vielzahl von Pumpen gesteuert wird, um ein erstes Medikament zu infundieren;
 wenn der mittlere Endblutdruck des Subjekts unter den Blutdruckschwellenwert fällt und die Herzfrequenz den Herzfrequenzschwellenwert unterschreitet, eine zweite Pumpe (240) der Vielzahl von Pumpen besteuert wird, um ein zweites Medikament zu infundieren;
 wenn der Blutdruck den Blutdruckschwellenwert überschreitet, die Vielzahl von Pumpen (170) deaktiviert wird und keine Infusion von Medikamenten eintritt;
 wobei die Steuereinheit geeignet ist, die Injektion von Medikamenten in das Subjekt in regelmäßigen Zeitabständen zwischen 15 und 30 Sekunden zu veranlassen, bis der Blutdruck den Blutdruckschwellenwert überschreitet.

2. System nach Anspruch 1, bei welchem der Blutdruckschwellenwert 90 % einer Blutdruck-Baseline unterschreitet.
3. System nach Anspruch 1 oder 2, bei welchem der Herzfrequenzschwellenwert 60 Schläge pro Minute unterschreitet.
4. System nach einem der vorhergehenden Ansprüche, bei welchem das erste Medikament Phenylephrin ist.
5. System nach einem der vorhergehenden Ansprüche, bei welchem das zweite Medikament Ephedrin ist.
6. System nach Anspruch 4 oder 5, bei welchem die Steuereinheit geeignet ist, eine Injektion von Phenylephrin mit einer Dosis zwischen ungefähr 0,01 mg bis 0,2 mg oder 0,025 mg in regelmäßigen Zeitabständen zu veranlassen.
7. System nach Anspruch 5 oder 6, bei welchem die Steuereinheit geeignet ist, eine Injektion von Ephedrin mit einer Dosis zwischen ungefähr 0,5 mg bis 4 mg oder 2 mg in regelmäßigen Zeitabständen zu veranlassen.
8. System nach einem der vorhergehenden Ansprüche, bei welchem die Blutdruckdatenerzeugungseinheit geeignet ist, die Blutdruckdaten in Echtzeit zu erzeugen.
9. System nach einem der vorhergehenden Ansprüche, bei welchem die Blutdruckdatenerzeugungseinheit optische Sensoren beinhaltet.
10. System nach Anspruch 9, bei welchem die Blutdruckdatenerzeugungseinheit eine Manschette ist, in welche die optischen Sensoren integriert sind, wobei die Manschette geeignet ist, mechanischen Druck auf das Subjekt aufzubringen.

Revendications

1. Système de contrôle d'une pression artérielle d'un sujet, comprenant :

une unité de génération de données de pression artérielle (430) qui est adaptée pour générer des données de pression artérielle qui indiquent la pression artérielle du sujet, et qui est en outre adaptée pour étalonner une ligne de base de pression artérielle pour le sujet et pour sélectionner un seuil de pression artérielle qui correspond à ladite ligne de base de pression artérielle ;
 ladite unité de génération de données de pression artérielle étant adaptée pour calculer une pression artérielle moyenne finale qui indique la pression artérielle du sujet pendant une période prédéterminée de telle sorte que la pression artérielle moyenne finale inclue une pondération plus importante accordée à la pression artérielle qui est mesurée dans une partie plus tardive de la période prédéterminée que pendant une partie davantage précoce ;
 dans lequel la pression artérielle est générée par une unité de génération de données de pression artérielle

non invasive, l'unité de génération de données de pression artérielle étant non invasive ;
 une unité de génération de données de rythme cardiaque qui est adaptée pour générer des données de rythme cardiaque qui indiquent un rythme cardiaque du sujet, et qui est en outre adaptée pour étalonner une ligne de base de rythme cardiaque pour le sujet et pour sélectionner un seuil de rythme cardiaque qui correspond à ladite ligne de base de rythme cardiaque ;
 une pluralité de pompes (450), dans lequel chacune de la pluralité de pompes est adaptée pour perfuser l'un d'une pluralité de différents médicaments sur le sujet, chacun de la pluralité de différents médicaments ayant une influence particulière sur la pression artérielle du sujet ;
 une unité de commande (440) qui est adaptée pour commander la pluralité de pompes pour perfuser, en fonction de la pression artérielle moyenne finale par rapport au seuil de pression artérielle et en fonction des données de rythme cardiaque par rapport au seuil de rythme cardiaque, un mélange de médicaments sur le sujet, lequel mélange stabilise la pression artérielle du sujet ; **caractérisé en ce que**
 les pompes de la pluralité de pompes sont commandées de telle sorte que,
 si la pression artérielle moyenne finale du sujet chute en deçà du seuil de pression artérielle et si le rythme cardiaque excède le seuil de rythme cardiaque, une première pompe (220) de la pluralité de pompes soit commandée pour perfuser un premier médicament ;
 si la pression artérielle moyenne finale du sujet chute en-deçà du seuil de pression artérielle et si le rythme cardiaque chute en-deçà du seuil de rythme cardiaque, une seconde pompe (240) de la pluralité de pompes soit commandée pour perfuser un second médicament ; et
 si la pression artérielle excède le seuil de pression artérielle, les pompes de la pluralité de pompes (170) soient désactivées et qu'aucune perfusion de médicaments ne soit réalisée ;
 dans lequel l'unité de commande est adaptée pour provoquer l'injection de médicaments sur le sujet selon des intervalles temporels réguliers qui s'inscrivent dans la plage qui est comprise entre 15 secondes et 30 secondes jusqu'à ce que la pression artérielle excède le seuil de pression artérielle.

2. Système selon la revendication 1, dans lequel le seuil de pression artérielle chute en-deçà de 90 % d'une pression artérielle de ligne de base.
3. Système selon la revendication 1 ou 2, dans lequel le seuil de rythme cardiaque chute en-deçà de 60 battements par minute.
4. Système selon l'une quelconque des revendications qui précèdent, dans lequel le premier médicament est la phényléphrine.
5. Système selon l'une quelconque des revendications qui précèdent, dans lequel le second médicament est l'éphédrine.
6. Système selon la revendication 4 ou 5, dans lequel l'unité de commande est adaptée pour provoquer l'injection de phényléphrine selon une dose entre environ 0,01 mg et 0,2 mg ou 0,025 mg selon des intervalles temporels réguliers.
7. Système selon la revendication 5 ou 6, dans lequel l'unité de commande est adaptée pour provoquer l'injection d'éphédrine selon une dose entre environ 0,5 mg et 4 mg ou 2 mg selon des intervalles temporels réguliers.
8. Système selon l'une quelconque des revendications qui précèdent, dans lequel l'unité de génération de données de pression artérielle est adaptée pour générer les données de pression artérielle en temps réel.
9. Système selon l'une quelconque des revendications qui précèdent, dans lequel l'unité de génération de données de pression artérielle comprend des capteurs optiques.
10. Système selon la revendication 9, dans lequel l'unité de génération de données de pression artérielle est un brassard à l'intérieur duquel les capteurs optiques sont intégrés, dans lequel le brassard est adapté pour appliquer une pression mécanique sur le sujet.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 61382945 [0001]
- WO 2006091650 A2 [0007]

Non-patent literature cited in the description

- **CYNA AM ; ANDREW M ; EMMETT RS ; MIDDLETON P ; SIMMONS SW.** Techniques for preventing hypotension during spinal anaesthesia for caesarean section. *Cochrane Database Syst Rev*, 2006, (4), CD002251 [0055]
- **ERKINARO T ; MÄKIKALLIO K ; KAVASMAA T ; ALAHUHTA S ; RÄSÄNEN J.** Effects of ephedrine and phenylephrine on uterine and placental circulations and fetal outcome following fetal hypoxaemia and epidural-induced hypotension in a sheep model. *Br J Anaesth.*, 2004, vol. 93 (6), 825-32 [0055]
- **HAWTHORNE, L. ; LYONS G.** Cardiac arrest complicating spinal anaesthesia for caesarean section. *Int J Obstet Anesth*, 1997, vol. 6 (2), 126-9 [0055]
- **NGAN KEE WD ; KHAW KS ; NG FF.** Comparison of phenylephrine infusion regimens for maintaining maternal blood pressure during spinal anaesthesia for Caesarean section. *Br J Anaesth.*, 2004, vol. 92 (4), 469-74 [0055]
- **NGAN KEE WD ; KHAW KS ; NG FF.** Prevention of hypotension during spinal anesthesia for cesarean delivery: an effective technique using combination phenylephrine infusion and crystalloid cohydration. *Anesthesiology*, 2005, vol. 103 (4), 744-50 [0055]
- **PARKER J ; BALIS N ; CHESTER S ; ADEY D.** Cardiopulmonary arrest in pregnancy: successful resuscitation of mother and infant following immediate caesarean section in labour ward. *Aust N Z J Obstet Gynaecol*, 1996, vol. 36 (2), 207-10 [0055]
- **ROBERTS SW ; LEVENO KJ ; SIDAWI JE ; LUCAS MJ ; KELLY MA.** Fetal acidemia associated with regional anesthesia for elective cesarean delivery. *Obstet Gynecol*, 1995, vol. 85 (1), 79-83 [0055]
- **ROOFTHOFT, E. ; M. VAN DE VELDE.** Low-dose spinal anaesthesia for Caesarean section to prevent spinal-induced hypotension. *Curr Opin Anaesthesiol*, 2008, vol. 21 (3), 259-62 [0055]
- **SMILEY RM BJ ; NEGRON M ; LANDAU R.** beta2-adrenoceptor genotype affects vasopressor requirements during spinal anesthesia for cesarean delivery. *Anesthesiology*, 2006, vol. 104 (4), 644-50 [0055]

专利名称(译)	药物输注系统和控制血压的方法		
公开(公告)号	EP2616121A4	公开(公告)日	2015-09-02
申请号	EP2011825543	申请日	2011-09-15
[标]申请(专利权)人(译)	新加坡保健服务集团有限公司		
申请(专利权)人(译)	新加坡保健服务有限公司		
当前申请(专利权)人(译)	新加坡保健服务有限公司		
[标]发明人	SIA TIONG HENG ALEX		
发明人	SIA, TIONG-HENG, ALEX		
IPC分类号	A61M5/142 A61B5/00 A61B5/021 A61B5/024 A61M5/14 A61M5/168 A61M5/172 G06F19/00		
CPC分类号	A61B5/021 A61B5/024 A61B5/4821 A61B5/4839 A61M5/142 A61M5/16804 A61M5/16827 A61M5/16877 A61M5/1723 A61M2005/14208 A61M2005/1726 G06F19/3468 G16H20/17 A61M5/1407 G06F19/00 G16H10/40		
代理机构(译)	庆祝活动，JENTSCHURA & PARTNER		
优先权	61/382945 2010-09-15 US		
其他公开文献	EP2616121A1 EP2616121B1		
外部链接	Espacenet		

摘要(译)

提供了涉及控制受试者的血压的方法的各种实施例，该方法包括产生指示受试者的血压的血压数据，根据血压数据控制多个泵输注药物进入所述受试者，其中所述多个泵中的每一个适于将多种不同药物中的一种注入所述受试者中，并且其中所述多种不同药物中的每一种对所述受试者的血压具有特定影响，其中所述多个控制泵的速度，使得根据血压数据，将药物混合物注入受试者体内，从而稳定受试者的血压。